Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions
Pancreatectomy for Chronic Pancreatitis
Interventions
DRUG

Reparixin

Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour

DRUG

Placebo

Physiologic solution administered at 0.25 mL/kg/hour

Trial Locations (9)

15213

Thomas E. Starzl Transplantation Institute University of Pittsburgh Medical Center, Pittsburgh

29425

Medical University of South Carolina, Charleston

45219

The University of Cincinnati Medical Center, Cincinnati

55455

Schulze Diabetes Institute University of Minnesota Medical School, Minneapolis

60637

The University of Chicago Medical Center, Chicago

75246

Baylor University Medical Center, Dallas

94143

University of California. Department of Surgery, Division of Transplantation, San Francisco

03756

Dartmouth-Hitchcock Medical Center, Lebanon

T6G 2C8

University of Alberta, Clinical Islet Transplant Program, Edmonton

All Listed Sponsors
lead

Dompé Farmaceutici S.p.A

INDUSTRY

NCT01967888 - Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation | Biotech Hunter | Biotech Hunter